Latest Contrast Nephropathy News
Contrast-associated acute kidney injury occurred in 9.5% and 9.1% of patients receiving IV sodium bicarbonate and acetylcysteine, respectively, rates which did not differ significantly from the 8.3% rate among those receiving IV sodium chloride.
In a phase 3 trial, acute kidney injury developed in 13.2% of patients undergoing invasive coronary angiography compared with 5.6% of those undergoing computed tomography angiography.
AKI occurred with similar frequency among patients who did and did not receive contrast medium.
Myocardial infarction patients who underwent percutaneous coronary intervention had an AKI rate similar to those who did not have the procedure.
Risk factors include impaired renal function and inadequate hydration prior to contrast exposure.
Compared with control treatment, RenalGuard therapy correlated with significantly reduced CI-AKI, as well as a reduced need for renal replacement therapy.
In a study, the odds of acute kidney injury were 7% lower among patients who received radiocontrast versus those who did not.
CIN developed in 14.7% of patients with low hemoglobin levels compared with 5% of those with normal levels.
N-acetylcysteine patients had significantly decreased odds of contrast-induced nephropathy.
CARIN trial reported no significant differences in acute kidney injury incidence between novel compound CMX-2043 and placebo.
Greatest reduction for N-acetylcysteine in patients receiving low-osmolar contrast media.
Risk is linked to small changes in serum creatinine and eGFR on the day after contrast exposure.
Reduced risk of contrast-induced nephropathy with no increase in acute heart failure.
Study reveals a 13% incidence of CIN in allograft recipients undergoing computed tomography or cardiac catheterization with contrast media.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)